rituximab for Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
MD Anderson Cancer Center, Houston, TX
Mantle Cell Lymphoma; Non-Hodgkin Lymphoma+3 More
rituximab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This study is evaluating whether a drug called zanubrutinib may help treat mantle cell lymphoma.

See full description

Eligible Conditions

  • Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Study Objectives

This trial is evaluating whether rituximab will improve 1 primary outcome and 7 secondary outcomes in patients with Mantle Cell Lymphoma; Non-Hodgkin Lymphoma. Measurement will happen over the course of Up to 7 years.

Up to 7 years
Duration of response (DOR)
Occurrence and severity of treatment-emergent adverse events (safety and tolerability)
Overall response rate (ORR)
Overall survival (OS)
PFS by investigator
PROs as assessed by the EORTC QLQ-C30 questionnaire
Participant-reported outcomes (PROs) as assessed by the EQ-5D-5L questionnaire
Progression-free survival (PFS) determined by independent central review

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Mantle Cell Lymphoma; Non-Hodgkin Lymphoma

Trial Design

2 Treatment Groups

bendamustine plus rituximab
1 of 2
zanubrutinib plus rituximab
1 of 2
Active Control
Experimental Treatment

This trial requires 500 total participants across 2 different treatment groups

This trial involves 2 different treatments. Rituximab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.

zanubrutinib plus rituximab
bendamustine plus rituximab
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Zanubrutinib
FDA approved
Rituximab
FDA approved

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 7 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly up to 7 years for reporting.

Closest Location

MD Anderson Cancer Center - Houston, TX

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 7 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
≥70 years of age at the time of informed consent, OR ≥60 and <70 years of age with comorbidities precluding autologous stem cell transplantation
Histologically confirmed diagnosis of MCL
No prior systemic treatments for MCL
Measurable disease by CT/MRI
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2
Adequate marrow and organ function
Key

Patient Q&A Section

What are common treatments for lymphoma, mantle-cell?

"Lymphomas have a similar treatment option based on the type; B-and T-cell lymphomas have more options in regards to surgery, radiation therapy, or targeted therapies. For mantle-cell lymphoma, chemotherapy with high-dose carboplatin and cyclophosphamide is typically the option of choice. For mantle-cell lymphoma patients who are younger than 65, autologous stem cell transplant is frequently used. B-cell lymphoma (e.g. Hodgkin's disease) may be treated with radiation therapy, and targeted therapy with abatacept or R-CHOP can be used in patients who do not respond to chemotherapy." - Anonymous Online Contributor

Unverified Answer

What causes lymphoma, mantle-cell?

"Most cases of lymphoma occur inside the lymph nodes or lymphatics. Cancer cells from these areas of the body are carried to the blood to form peripheral lymphoma. If the cancer cells spread to other parts of the body, the lymphoma becomes nodal lymphoma. The cells can become cancerous when they are able to divide freely in the blood, which they cannot do in the lymph node or lymphatics. This leads to the different types of lymphoma. The genetic changes involved in this process are the cause of mantle-cell lymphoma." - Anonymous Online Contributor

Unverified Answer

What are the signs of lymphoma, mantle-cell?

"Symptoms of mantle-cell lymphoma are often non-specific. However, the most common sign is a palpable enlarged lymph node. Signs of other lymphoma are more specific and usually" - Anonymous Online Contributor

Unverified Answer

Can lymphoma, mantle-cell be cured?

"Although MCD is very rare. In our series with 10 patients, none of the 10 were cured. Treatment options for patients with MCD are not well established, other than aggressive chemotherapy for acute illnesses. We may not have the optimal treatment for the disorder to determine its curability. However, we were able to find a case of cure in the MCD, and that patient is the only one who has undergone successful treatment for the disease. More research is needed to explore other optimal treatment options." - Anonymous Online Contributor

Unverified Answer

How many people get lymphoma, mantle-cell a year in the United States?

"Each year, 7.8 million Americans are diagnosed with a lymphoma. This makes up 16.3% of American adults. In the United States, women are more commonly diagnosed with mantle-cell lymphoma than men. This is probably due to the fact that, in industrialized countries, mantle-cell lymphoma can be associated with low birth weights and other immunodeficiencies." - Anonymous Online Contributor

Unverified Answer

What is lymphoma, mantle-cell?

"The cells that make up lymphoma are usually found in the immune system. They may be B cells, T cells, NK cells, or monocytes. The most common type of lymphoma, non-Hodgkin's lymphoma is a cancer that develops in the immune system. Most people develop lymphoma after a long period of time, in which time the cancer cells reproduce and spread throughout the body." - Anonymous Online Contributor

Unverified Answer

What is the primary cause of lymphoma, mantle-cell?

"This analysis suggests that a significant portion of people with mantle-cell lymphoma are HIV infected or have some other type of immunosuppression. Data from a recent study support the hypothesis that the primary cause of mantle cell lymphoma is HIV infection or immunosuppression associated with HIV. This article is protected by copyright. All rights reserved." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets lymphoma, mantle-cell?

"On average, lymphoma is diagnosed at age 61. answer: On average, lymphoma is diagnosed at age 61. This finding suggests a role for early diagnosis, which may result in a cure for early lymphoma. The findings can guide patient education, encourage patients for early referral to a cancer center, and improve access to lymphoma treatment for underutilized and under-served patients." - Anonymous Online Contributor

Unverified Answer

Is rituximab typically used in combination with any other treatments?

"In a recent study, findings, patients in the rituximab-only group had higher DFS and OS than patients with other combinations of treatments. In a recent study, findings suggests that rituximab alone has an indication for patients with mantle cell lymphoma." - Anonymous Online Contributor

Unverified Answer

Does lymphoma, mantle-cell run in families?

"Results from a recent clinical trial, in addition to the known associations between the HLA genotypes, the CD34 and M-HC variants, and the immunoglobulin allotypes, no particular genetic risk factors for LMCL were detected." - Anonymous Online Contributor

Unverified Answer

Has rituximab proven to be more effective than a placebo?

"Rituximab as a single-agent was highly effective in relapsed or refractory MCL and was significantly more effective than a placebo, even with the previous use of B-CASP. Results from a recent clinical trial of this study provide good evidence that rituximab improves the prognosis and reduces relapses in patients with relapsed or refractory MCL. However, a large, prospective, controlled study is warranted." - Anonymous Online Contributor

Unverified Answer

Who should consider clinical trials for lymphoma, mantle-cell?

"The number of lymphoma patients and the ratio of newly developed agents to available agents make these trials relevant. This article provides practical guidelines for patients who want to join a trial or considering clinical trials." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Mantle Cell Lymphoma; Non-Hodgkin Lymphoma by sharing your contact details with the study coordinator.